Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by social deficits, communication issues, and repetitive behaviors.
• Genetic and environmental factors, including prenatal infections, are implicated in ASD etiology.
• Our prior research demonstrated that prenatal exposure to lipopolysaccharide (LPS) induces autistic-like behaviors in a rat model.

Purpose of the Study:

• To investigate the therapeutic potential of pioglitazone for treating LPS-induced autistic-like behaviors in a juvenile rat model.
• To evaluate the effects of pioglitazone on social interaction and communication deficits.
• To explore the underlying mechanisms by examining key biomarkers.

Main Methods:

• Rats were exposed to LPS prenatally to induce autistic-like behaviors.
• Juvenile offspring received daily postnatal treatment with pioglitazone.
• Socialization (play behavior) and communication (50-kHz ultrasonic vocalizations) were assessed.
• Plasma levels of IL-6, TNF-alpha, MCP-1, insulin, and leptin were measured.

Main Results:

• Prenatal LPS exposure resulted in social deficits, communication abnormalities, and elevated plasma IL-6 levels in juvenile rats.
• Postnatal pioglitazone treatment successfully reversed the social interaction impairments.
• Pioglitazone treatment normalized ultrasonic vocalizations and reduced elevated IL-6 levels.

Conclusions:

• Pioglitazone effectively ameliorates autistic-like behaviors and associated neuroinflammation in a rat model.
• These findings highlight pioglitazone as a promising therapeutic candidate for autism treatment.
• Further research into pioglitazone's mechanisms may advance understanding and treatment of autism and related disorders.